Effects of Lasoperin™ on cognitive function in healthy adults

INTERVENTION: In a randomized, double‐blind, placebo‐controlled fashion, study participants will be required to ingest either a placebo or supplement (Scutellaria baicalensis [241 mg] and Acacia catechu extracts [ 51 mg]. All participants will consume 1 dose (1 capsule) of their assigned supplement daily for 30 days. CONDITION: Cognitive function, well‐being and mood, inflammation, brain health, oxidative stress, and quality of life in healthy adults ; Not Applicable PRIMARY OUTCOME: Cognitive function is measured using the Flanker Inhibitory Control and Attention Test, Dimensional Change Card Sort Test, and Pattern Comparison Processing Speed Test at baseline, 2 weeks, and 4 weeks. SECONDARY OUTCOME: ; 1. Well‐bring and mood measured using the NIH Toolbo XGeneral Life Satisfaction Questionnaire at baseline, 2 weeks, and 4 weeks; 2. Cognitive interference, visual attention, and motor functioning measured using the Stroop color test, Trail Making Test Part A and B, and Finger Tapping Test at baseline, 2 weeks, and 4 weeks; 3. Inflammation, brain health, and oxidative stress measured using plasma C‐Reactive protein (CRP), plasma cortisol, plasma brain‐derived neurotrophic factor (BDNF), and serum uric acid at baseline, 2 weeks, and 4 weeks; 4. Quality of life measured using the RAND 36‐item short form (SF‐36) survey at baseline, 2 weeks, and 4 weeks; INCLUSION CRITERIA: 1. Healthy adult participants who are 30 to 60 years of age (inclusive) 2. In good general health (no active or uncontrolled diseases or conditions) 3. Have a body mass inde X(BMI) between 18.0 to 34.9 kg/m² (inclusive) 4. Have normal or acceptable to the investigator vital signs (blood pressure and heart rate) at screening and/or baseline 5. Individuals with childbearing potential must agree to practice an acceptable form of birth control for a certain timeframe prior to the first dose of the study product and throughout the study, including: 5.1. Use for at least 3 months prior to the first dose of study product: hormonal contraceptives including oral contraceptives, hormone birth control patch (e.g., Ortho Evra), vaginal contraceptive ring (e.g., NuvaRing), injectable contraceptives (e.g., Depo‐Provera, Lunelle), or hormone implant (e.g., Norplant System); or 5.2. Use for at least 1 month prior to the first dose o